New use of inhaled long-acting bronchodilators (long-acting β2-agonists [LABAs] or long-acting antimuscarinic antagonists [LAMAs]) in patients with chronic obstructive pulmonary disease (COPD) is associated with 1.5-fold increase in the risk of cardiovascular disease (CVD) within a month of starting treatment. These findings from an observational study were published online January 2, 2018 in JAMA Internal Medicine.